Summary:
The purpose of this study is to compare the efficacy and safety of adalimumab versus approved reference drug, Humira in subjects with chronic Psoriasis.
Qualified Participants Must:
• Be at least 18 years of age
•
Have a diagnosis of chronic plaque-type psoriasis at least 6 months prior to screening visit
Qualified Participants May Receive:
Study medications, visits to the study doctor, laboratory tests and procedures performed for the study will be provided at no charge to you or your insurance. Qualified participated will be compensated $50 per each completed visit.